(Press-News.org) Ovarian clear cell carcinoma is difficult to treat, and treatment options are limited
Patients with specific PPP2R1A mutations in their tumors survived significantly longer after immunotherapy treatment
Targeting PPP2R1A may improve responses even further according to laboratory studies
PPP2R1A is an important predictive biomarker and possible treatment target for multiple cancer types, study found
HOUSTON, JULY 2, 2025 ― Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without these mutations, according to researchers from The University of Texas MD Anderson Cancer Center.
The findings, published today in Nature, suggest PPP2R1A mutations could be a valuable biomarker to help guide treatment for this difficult-to-treat ovarian cancer subtype and may offer a new therapeutic target to further improve outcomes in multiple cancer types.
Results of the study found that patients with PPP2R1A-mutant OCCC had a median overall survival (OS) of more than five years (66.9 months) after immunotherapy treatment, compared to just 9.2 months for patients without this mutation.
“Developing effective immunotherapies for ovarian cancer, including rare subtypes like ovarian clear cell carcinoma, remains a significant unmet clinical need,” said co-senior author Amir Jazaeri, M.D., professor of Gynecologic Oncology and Reproductive Medicine. “Our study is the first to demonstrate the clinical importance of PPP2R1A mutations, and it opens the door to new strategies that could benefit many more patients.”
In a Phase II trial, researchers investigated outcomes in a cohort of 34 patients with treatment-resistant OCCC who had been treated with a combination of immune checkpoint inhibitors – durvalumab and tremelimumab. Based on their findings in OCCC, experts also looked at two additional independent cohorts, one consisting of patients with endometrial cancer and the other including more than 9,000 patients with multiple cancer types who received immunotherapy treatment. Analyses confirmed the improved OS following immunotherapy in those with tumor PPP2R1A mutations.
In parallel, laboratory research showed that targeting PPP2R1A both in vitro and in vivo was also associated with improved response to immunotherapy, suggesting a causal link. This too indicates that therapies targeting PPP2R1A and the associated protein phosphatase 2A (PP2A) molecular pathway could be added to immunotherapy to further boost outcomes.
“Not only did we identify a new biomarker in ovarian cancer, but we also confirmed survival benefits in other cancer types,” Jazaeri said. “Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A pathway --using drugs, and we currently are evaluating this in a clinical trial at MD Anderson.”
The study represents an ongoing collaboration across multiple disciplines, led by co-senior authors Jazaeri; Linghua Wang, M.D., Ph.D., associate professor of Genomic Medicine and associate member of the James P. Allison Institute and focus area co-lead with the Institute for Data Science in Oncology; and Rugang Zhang, Ph.D., chair of Experimental Therapeutics.
This research was co-lead by first authors Yibo Dai and Minghao Dang, Ph.D., of the Wang laboratory; Anne Knisely, M.D., fellow in Gynecologic Oncology and Reproductive Medicine; and Mitsutake Yano, M.D., Ph.D., postdoctoral fellow in the Zhang laboratory. A full list of collaborating authors and their disclosures can be found in the paper.
This study was supported through grants from the National Institutes of Health/National Cancer Institute (T32 CA101642, R01CA202919, R01CA239128, R01CA243142, R01CA260661, R01CA276569, P50CA281701 and P50CA272218, K07CA201013), Dunwoody-Reese Philanthropic, MD Anderson’s Ovarian Cancer Moon Shot, the U.S. Department of Defense (OC190181, OC210124, OC180193), the Cancer Prevention and Research Institute of Texas, Pennsylvania Department of Health CURE Funds, the Robert I. Jacobs Fund of The Philadelphia Foundation, the American Cancer Society (CA281701), and Frank McGraw Memorial Chair in Cancer Research.
END
New genetic marker linked to improved survival with immunotherapy in ovarian and other cancers
2025-07-02
ELSE PRESS RELEASES FROM THIS DATE:
AI that thinks like us – and could help explain how we think
2025-07-02
Researchers at Helmholtz Munich have developed an artificial intelligence model that can simulate human behavior with remarkable accuracy. The language model, called Centaur, was trained on more than ten million decisions from psychological experiments – and makes decisions in ways that closely resemble those of real people. This opens new avenues for understanding human cognition and improving psychological theories.
For decades, psychology has aspired to explain the full complexity of human thought. Yet traditional models could either offer a transparent ...
The imitation game – why are some species better at fooling predators than others?
2025-07-02
Experts from the University of Nottingham have created life-size 3D-printed insect models to explore how some species trick predators into thinking they're more dangerous than they really are — and avoid being eaten as a result.
In the new study, published in Nature, a team of experts, led by Dr Tom Reader and Dr Christopher Taylor in the School of Life Sciences, used 3D printed models to investigate Batesian mimicry – a phenomenon where a harmless species evolves to resemble a harmful species, fooling ...
Gas leakage triggers wound healing in plants
2025-07-02
Scientists at the University of Helsinki discovered how plants heal their protective outer layer, the periderm. The diffusion of ethylene and oxygen through a wound triggers repair – a finding with potential implications for crop resilience, and food preservation.
All living organisms rely on protective barrier tissues to shield them from the environment. In plants, the periderm which forms the tough outer cork layer plays this role, helping to prevent water loss and block harmful microbes, for example in potato skin and tree bark. But what happens ...
Forging a novel therapeutic path for patients with Rett Syndrome using AI
2025-07-02
Forging a novel therapeutic path for patients with Rett Syndrome using AI
AI-enabled drug discovery approach identified potentially game-changing treatment which has been advanced from the lab bench to an FDA Orphan Drug Designation in record time
By Benjamin Boettner
(BOSTON) — Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are born with it and much fewer boys. It is caused by mutations in the MeCP2 gene on the X chromosome, leading to a spectrum of cognitive and physical impairments, including ...
Global drought hotspots report catalogs severe suffering, economic damage in 2023-2025
2025-07-02
Fuelled by climate change and relentless pressure on land and water resources, some of the most widespread and damaging drought events in recorded history have taken place since 2023, according to a UN-backed report launched today.
Prepared by the U.S. National Drought Mitigation Center (NDMC) and the UN Convention to Combat Desertification (UNCCD), with support from the International Drought Resilience Alliance (IDRA), the report, "Drought Hotspots Around the World 2023-2025," provides a comprehensive account of how droughts compound poverty, ...
Study: To battle tip fatigue, businesses should make their service efforts visible
2025-07-02
PULLMAN, Wash. -- As customers face more and more prompts to add a tip to the bill in places where gratuities were not customary only a few years ago—and often before any service has been rendered—their attitudes toward the practice have turned sharply negative.
“Businesses should seriously consider whether they want to offer that tipping request,” said Ruiying Cai, an assistant professor in the WSU’s Carson College of Business and co-author of a new study published in the International Journal of Hospitality ...
This spongy material and the sun’s power remove salt from seawater
2025-07-02
Most of Earth’s water is in the oceans and too salty to drink. Desalination plants can make seawater drinkable, but they require large amounts of energy. Now, researchers reporting in ACS Energy Letters have developed a sponge-like material with long, microscopic air pockets that uses sunlight and a simple plastic cover to turn saltwater into freshwater. A proof-of-concept test outdoors successfully produced potable water in natural sunlight in a step toward low-energy, sustainable desalination.
This isn’t the first time scientists have created spongy materials that use sunlight as ...
Nearly 1 in 6 older adults take aspirin despite no history of heart disease
2025-07-02
Around 1 in 6 older adults take aspirin as their primary method of preventing cardiovascular disease – despite stricter guidelines that no longer always call for it, a study finds.
Almost one-quarter of those aspirin users started taking the medication without a physician recommendation and 8% had not discussed their use with any health care provider.
The results, published in the Journal of the American College of Cardiology, come from a survey of more than 2,500 adults aged ...
ACMG takes action to address national gap in newborn screening leadership
2025-07-02
BETHESDA, MD – July 2, 2025 | In response to the continued need for evidence-based reviews of newborn screening (NBS) conditions following the recent dissolution of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), the American College of Medical Genetics and Genomics (ACMG) is moving forward with organizing a new advisory framework to uphold the integrity and scientific rigor of nationally coordinated NBS recommendations.
To initiate this process, the ACMG will convene a virtual stakeholder roundtable this summer to gather ...
Stopping pancreatic cancer spread using benzaldehyde
2025-07-02
Cancer cells have the capacity to multiply rapidly. The aggressive cancer cells undergo conversion from their tightly connected epithelial state into a mesenchymal state, which lacks contact restrictions and spreads easily to other parts of the body. Such epithelial-to-mesenchymal plasticity also makes the cancer cells resistant to elimination by anticancer therapies.
The search is ongoing for newer anticancer agents that can overcome this acquired resistance to therapy and destroy the ‘rogue’ cancer cells. A group of researchers led by Dr. Hideyuki Saya, Director of the Oncology Innovation Center, Fujita Health University, ...